Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same author

How does the Calibre learning program impact attitudes towards caring for patients who have obesity?

Obesity pillars·2026
Same author

A Longitudinal Study Exploring the Influence of Weight Bias Internalization and Weight-Based Discrimination on Pathological Eating After Metabolic and Bariatric Surgery.

Obesity surgery·2026
Same author

Obesity care education in Canadian medical schools: A multi-site qualitative study.

Obesity pillars·2026
Same author

Building a data-driven evaluation framework of physician wellness initiatives: a rapid review.

BMJ open·2026
Same author

Development of Virtual Mental Health Stepped Care Service for a Heart Failure Remote Management Program: Qualitative Descriptive Study.

JMIR formative research·2026

Related Experiment Video

Updated: Jun 20, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Managing depression during hepatitis C treatment.

Sanjeev Sockalingam1, Susan E Abbey

  • 1Program in Medical Psychiatry, Toronto General Hospital, University Health Network, Toronto, Ontario. sanjeev.sockalingam@uhn.on.ca

Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|September 16, 2009
PubMed
Summary

Hepatitis C virus (HCV) patients often experience depression during interferon-alpha (IFN-alpha) treatment. Antidepressant prophylaxis and treatment, particularly with SSRIs, are effective strategies for managing IFN-alpha-induced major depressive disorder (IFN-alpha-MDD).

Related Experiment Videos

Last Updated: Jun 20, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Area of Science:

  • Hepatology
  • Psychiatry
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection affects 1% of Canadians, with increasing prevalence expected.
  • Depression is common in HCV patients and can hinder interferon-alpha (IFN-alpha) treatment.
  • Interferon-alpha-induced major depressive disorder (IFN-alpha-MDD) is a significant clinical challenge.

Purpose of the Study:

  • To review risk factors for IFN-alpha-MDD in HCV patients.
  • To evaluate evidence for antidepressant prophylaxis and symptomatic treatment of depression during IFN-alpha therapy.

Main Methods:

  • Searched MEDLINE, EMBASE, and CINAHL for relevant randomized controlled trials and quasi-experimental studies.
  • Conducted manual searches of references from review articles, case series, and anecdotal reports.

Main Results:

  • Summarized findings from 9 trials on prophylactic and symptomatic treatments for IFN-alpha-MDD.
  • Antidepressant pretreatment benefits patients with baseline depressive symptoms or prior IFN-alpha-MDD.
  • Selective serotonin reuptake inhibitors (SSRIs) show safety and efficacy in treating IFN-alpha-associated depression.

Conclusions:

  • Both prophylactic and symptomatic antidepressant treatments are effective for IFN-alpha-MDD.
  • Integrated medical and mental health approaches improve HCV treatment outcomes.
  • Early identification of depression is crucial for managing HCV patients on IFN-alpha therapy.